| 1 | India's contract drug makers: sector model |
| 2 | Kavish Raj Singh · Investace Capital Research · investacecapital.com/research/cdmo |
| 3 | Rs crore unless a column says otherwise. |
| 4 | Company data: stockscans.in. Prices at the 30 Oct 2026 close. |
| 5 | The question: Where does a contract drug manufacturer earn more than its cost of capital, for how long, and what does the price already assume? |
|
| 7 | Sheets |
| 8 | Universe: every listed name, sorted by business model. Revenue, margin, cost, cash cycle, valuation on one EV basis. |
| 9 | Capital: what each extra Rs 100 of revenue cost in capital, the return on that capital, and cash flow against capex before and after interest. The sheet to argue from. It shows both start years, FY23 and FY24. Capital employed is a formula: change a blue equity, reserves or borrowings cell at the far right and it moves. |
| 10 | Leverage: net debt / EBITDA, interest cover, short-term debt and any guided capex, per company. |
| 11 | What price assumes: the EBITDA growth each price needs to earn your required return, over 3 and 5 years, against what the company delivered from two base years, name by name, with sector medians at the foot. Change the inputs. |
| 12 | Shortlist filter: two tests on every company, return on new capital in both windows and growth delivered against growth needed. A filter for where to read first. |
| 13 | Justified multiple: what EV/EBITDA a given growth rate and return on new capital can support, at a cost of capital of 11%, 12% and 13%. |
| 14 | Molecule capture: dose x patients x days, then price per kg: how much of a drug's sales its supplier can earn. Rows are backed out to fit public estimates, so they show a method, not a measurement. |
| 15 | Funnel value: what a molecule at each clinical phase is worth to a CDMO, as the present value of pre-tax EBITDA, with retention flat and by stage. |
| 16 | J-curve: one plant from commissioning to full. Change the ramp and watch ROCE and payback. An example on assumed inputs, with fixed cost tested against the accounts. |
| 17 | Red and green sit inside the numbers. Green means the number passes the test on that sheet, red means it fails, and numbers in between stay uncoloured. |
| 18 | Green is not a buy signal and red is not a sell signal. A colour reports one test on one number, nothing more. |
| 19 | Conventions |
| 20 | Blue on pale blue: an input. Change it. Black: a formula. Every input carries its source on the sheet. |
| 21 | Fiscal years end in March. TTM is the latest twelve months the data holds, and it ends on different dates across names. |
| 22 | Inputs marked Our assumption are ours, to be replaced. Inputs marked Published estimate come from secondary sources and are leads, not checked facts. |
| 23 | Before tax and after tax: EBIT returns on Capital are before tax. The 12% cost of capital and 15% required return are after-tax numbers. At a 25% tax rate, 16% before tax is about 12% after tax and 20% is about 15%, and the colours use 16% and 20%. |
|
| 25 | Limits |
| 26 | Capital employed = equity + reserves + borrowings, which include leases, at year end. Cash is not netted, so cash-rich names look less efficient than they are. Non-controlling interest and share-warrant money are left out of capital and EV, while EBIT and EBITDA are 100% of subsidiaries. |
| 27 | Net debt is borrowings incl. leases less cash and bank, at 31 March. It is not complete: liquid funds sit outside the cash field. Read it from the balance sheet for any name discussed. |
| 28 | EV is market cap + our net debt, one basis for every name. Market cap is at the pull date and net debt at 31 March, so a raise in between is in one and not the other. |
|---|